

4. (Amended) A dormancy-control pentapeptide having an amino acid sequence of Asp-Ile-Leu-Arg-Gly (SEQ ID NO:1), a molecular weight of 570.959 and dormancy-control activity, wherein the C-terminal is amidated.

5. (Amended) The dormancy-control pentapeptide as set forth in claim 4, wherein the dormancy-control pentapeptide is derived from pre-larvae of *Antheraea yamamai*.

6. (Amended) A method for preparing a dormancy-control pentapeptide, comprising the steps of  
adding an acid-methanol solution consisting of methanol: water: acetic acid to pulverized pre-larvae of an insect;  
tritulating the resulting mixture;  
centrifuging the mixture; and  
subjecting the resulting supernatant to reverse phase high performance liquid chromatography and mixing-separation mode high performance liquid chromatography to give a dormancy-control pentapeptide, which has an amino acid sequence of Asp-Ile-Leu-Arg-Gly (SEQ ID NO:1) and a molecular weight of 570.959, wherein the C-terminal is amidated.

7. (Amended) A biological cell-control agent comprising, as an effective component, a pentapeptide having an amino acid sequence of Asp-Ile-Leu-Arg-Gly (SEQ ID NO:1), a molecular weight of 570.959, wherein the C-terminal is amidated.

8. (Amended) The biological cell-control agent as set forth in claim 7, which is a cancer cell-control agent.

9. (Amended) The biological cell-control agent as set forth in claim 7 or 8, wherein the pentapeptide is derived from pre-larvae of *Antheraea yamamai*.

10. (Amended) A biological cell-control agent comprising, as an effective component, a tetrapeptide having an amino acid sequence of Ile-Leu-Arg-Gly (SEQ ID NO:2) and a molecular weight of 456.58, wherein the C-terminal is amidated.

11. (Amended) The biological cell-control agent as set forth in claim 10, which is a cancer cell-control agent.

12. (Amended) The biological cell-control agent as set forth in claim 10 or 11, wherein the tetrapeptide is derived from pre-larvae of *Antheraea yamamai*.

Kindly add new claims 13-17 as set forth below.

13. (New) A dormancy-control pentapeptide having an amino acid sequence of Asp-Ile-Leu-Arg-Gly (SEQ ID NO:1) and dormancy-control activity.

14. (New) A biological cell-control agent comprising, as an effective component, a dormancy-control pentapeptide as set forth in claim 13.

15. (New) The biological cell-control agent as set forth in claim 14, which is a cancer cell-control agent.

16. (New) A biological cell-control agent comprising, as an effective component, a tetrapeptide having an amino acid sequence of Ile-Leu-Arg-Gly (SEQ ID NO:2).

17. (New) The biological cell-control agent as set forth in claim 16, which is a cancer cell-control agent.

#### REMARKS

With the addition of claims 13-17, claims 1-17 are pending.

The replacement of "protein" with "pentapeptide" in claims 1-7 and 9 would not narrow the scope of the amended claim recitation because it would have been apparent to a person skilled in the art that a protein having an amino acid sequence of DILRG is a pentapeptide. Similarly, the replacement of "peptide" with "tetrapeptide" in claims 10 and 12 would not narrow the scope of the amended claim recitation because it would have been apparent to a person skilled in the art that a protein having an amino acid sequence of ILRG is a tetrapeptide. The rest of the amendment to the claims is merely cosmetic and would not affect the scope of the amended claim recitations.

The new claims 13-17 are supported by the specification at page 15, line 20, page 16, the paragraph starting line 4 and page 36, the paragraphs starting line .8 or 24.